-
EP3362065
European procedure
Extract from the Register of European Patents
EP About this file: EP3362065
| EP3362065 - COMBINATION THERAPY COMPRISING IVOSIDENIB, CYTARABINE AND DAUNORUBICIN OR IDARUBICIN FOR TREATING ACUTE MYELOGENOUS LEUKEMIA [Right-click to bookmark this link] | |||
| Former [2018/34] | COMBINATION THERAPY FOR TREATING MALIGNANCIES | ||
| [2023/21] | Status | The patent has been granted Status updated on 01.03.2024 Database last updated on 13.11.2024 | |
| Former | Grant of patent is intended Status updated on 01.11.2023 | ||
| Former | Examination is in progress Status updated on 10.10.2023 | ||
| Former | Grant of patent is intended Status updated on 18.06.2023 | ||
| Former | Examination is in progress Status updated on 16.05.2020 | ||
| Former | Request for examination was made Status updated on 20.07.2018 | ||
| Former | The international publication has been made Status updated on 21.04.2017 | Most recent event Tooltip | 29.03.2024 | Change - divisional application(s) | published on 01.05.2024 [2024/18] | Applicant(s) | For all designated states Les Laboratoires Servier 50 rue Carnot 92284 Suresnes Cedex / FR | [2022/04] |
| Former [2021/40] | For all designated states Les Laboratoires Servier SAS 50 rue Carnot 92284 Suresnes Cedex / FR | ||
| Former [2018/34] | For all designated states Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
AGRESTA, Samuel, V. 24 Coolidge Road Lexington, MA 02420 / US | [2018/34] | Representative(s) | Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE | [2024/14] |
| Former [2018/34] | Bösl, Raphael Konrad Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstraße 68 81675 München / DE | Application number, filing date | 16856274.2 | 14.10.2016 | [2018/34] | WO2016US57036 | Priority number, date | US201562242267P | 15.10.2015 Original published format: US 201562242267 P | US201562255253P | 13.11.2015 Original published format: US 201562255253 P | [2018/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017066566 | Date: | 20.04.2017 | Language: | EN | [2017/16] | Type: | A1 Application with search report | No.: | EP3362065 | Date: | 22.08.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.04.2017 takes the place of the publication of the European patent application. | [2018/34] | Type: | B1 Patent specification | No.: | EP3362065 | Date: | 03.04.2024 | Language: | EN | [2024/14] | Search report(s) | International search report - published on: | US | 20.04.2017 | (Supplementary) European search report - dispatched on: | EP | 17.05.2019 | Classification | IPC: | A61K31/4439, C07H19/06, A61K45/06, A61P35/02, A61K31/7068, A61K31/704, A61K31/136, A61K31/7048, A61K31/444 | [2019/25] | CPC: |
A61K31/444 (EP,IL,US);
A61K31/4439 (IL,KR);
A61K31/136 (EP,IL,US);
A61K31/137 (IL,KR);
A61K31/704 (EP,IL,KR,US);
A61K31/7048 (EP,IL,US);
A61K31/7068 (EP,IL,KR,US);
A61P35/00 (IL,KR);
A61P35/02 (EP,IL,US);
C07D403/14 (IL,US);
C07H15/252 (EP,IL,US);
C07H19/09 (EP,IL,US);
A61K2300/00 (IL,KR)
(-)
| C-Set: |
A61K31/136, A61K2300/00 (EP);
A61K31/444, A61K2300/00 (EP);
A61K31/7048, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP); |
| Former IPC [2018/34] | A61K31/4439, C07H19/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/34] | Extension states | BA | 14.05.2018 | ME | 14.05.2018 | Validation states | MA | 14.05.2018 | MD | 14.05.2018 | Title | German: | KOMBINATIONSTHERAPIE MIT IVOSIDENIB, CYTARABINE UND DAUNORUBICIN ODER IDARUBICIN ZUR BEHANDLUNG VON AKUTER MYELOISCHER LEUKÄMIE | [2023/47] | English: | COMBINATION THERAPY COMPRISING IVOSIDENIB, CYTARABINE AND DAUNORUBICIN OR IDARUBICIN FOR TREATING ACUTE MYELOGENOUS LEUKEMIA | [2023/47] | French: | POLYTHÉRAPIE CONTENANT IVOSIDENIB, CYTARABINE ET DAUNORUBICIN OU IDARUBICIN POUR LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË | [2023/21] |
| Former [2018/34] | KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON MALIGNITÄTEN | ||
| Former [2018/34] | COMBINATION THERAPY FOR TREATING MALIGNANCIES | ||
| Former [2018/34] | POLYTHÉRAPIE POUR LE TRAITEMENT DE MALIGNITÉS | Entry into regional phase | 14.05.2018 | National basic fee paid | 14.05.2018 | Search fee paid | 14.05.2018 | Designation fee(s) paid | 14.05.2018 | Examination fee paid | Examination procedure | 14.05.2018 | Examination requested [2018/34] | 14.05.2018 | Date on which the examining division has become responsible | 12.12.2019 | Amendment by applicant (claims and/or description) | 20.05.2020 | Despatch of a communication from the examining division (Time limit: M06) | 27.11.2020 | Reply to a communication from the examining division | 06.05.2021 | Despatch of a communication from the examining division (Time limit: M04) | 16.09.2021 | Reply to a communication from the examining division | 19.06.2023 | Communication of intention to grant the patent | 09.10.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 02.11.2023 | Communication of intention to grant the patent | 21.02.2024 | Fee for grant paid | 21.02.2024 | Fee for publishing/printing paid | 21.02.2024 | Receipt of the translation of the claim(s) | Divisional application(s) | EP24166472.1 | Fees paid | Renewal fee | 29.10.2018 | Renewal fee patent year 03 | 28.10.2019 | Renewal fee patent year 04 | 27.10.2020 | Renewal fee patent year 05 | 27.10.2021 | Renewal fee patent year 06 | 27.10.2022 | Renewal fee patent year 07 | 27.10.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2012078288 (UNIV WASHINGTON [US], et al); | [Y]US2013190249 (LEMIEUX RENE M [US], et al); | [A]US2014187435 (DANG LEONARD LUAN C [US], et al); | Examination | WO2012151451 | by applicant | US2013190249 | WO2015138837 | WO2015138839 |